MaxSuppressor™ In Vivo RNA-LANCEr II

Catalog# Product Name Quantity US List Price
3410-01 MaxSuppressor™ In Vivo RNA-LANCEr II 20 injections $597 Buy Now

  • Robust in vivo delivery agent - Efficient at penetrating tissues and organs
  • Flexible – Works with multiple RNAi agents and routes of delivery
  • Gentle and non-toxic
  • Custom solutions for delivery available

The patented MaxSuppressor™ In Vivo RNA-LANCEr II is a proprietary formulation composed of neutral lipid, non-ionic detergent, oil and small molecules which enables highly efficient delivery of RNAi agents into animals. This novel product has been shown to be more robust and efficient at penetrating tissues and organs than other delivery agents.

The procedure to package RNAi agents into the phospholipid-oil emulsion takes less than 1-hour. To use MaxSuppressor In Vivo RNA-LANCEr II simply mix 100 µg of your RNAi agent with a single tube of semi-dry MaxSuppressor In Vivo RNA-LANCEr II agent in total volume of less than 300 µL, in 1X PBS; extrude using the Lipid Extruder with the supplied 100 nm pore sizing filters (or sonicate) and then directly inject into the animal.

Selected Publications that Reference Using the MaxSuppressor In Vivo RNA-LANCEr II

Alhasan, L. Design and Development of miRNA and stem cell based micro/nano systems as lung disease therapy. Dissertation. RMIT University, 2016. 

Amodio, N, et al. (2012) DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget 3(10): 1246-1258.

Di Martino, M.T. et al. (2013) In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma. Oncotarget 4(2): 242-255.

De Vito C, et al. (2011) Let-7a Is a Direct EWS-FLI-1 Target Implicated in Ewing’s Sarcoma Development. PLoS ONE 6(8): e23592. doi:10.1371/journal.pone.0023592 

De Vito C, et al. (2012) A TARBP2-Dependent miRNA Expression Profile Underlies Cancer Stem Cell Properties and Provides Candidate Therapeutic Reagents in Ewing Sarcoma. Cancer Cell. DOI 10.1016/j.ccr.2012.04.023.

Good, R., et al. (2016) Dysregulated MicroRNAs (miRNAs) in Pediatric Acute Respiratory Distress Syndrome (ARDS) and Animal Models of Acute Lung Injury: Focus on miR-26a and EphA2. RESPIRATORY FAILURE: MECHANISTIC INSIGHTS FROM LUNG INJURY MODELS. A6280-A6280.

Hatano, K., et al. (2015) A functional screen identifies miRNAs that inhibit DNA repair and sensitize prostate cancer cells to ionizing radiation. Nucl. Acids Res. doi: 10.1093/nar/gkv273.

Imam JS, Plyler JR, Bansal H, Prajapati S, Bansal S, et al. (2012) Genomic Loss of Tumor Suppressor miRNA-204 Promotes Cancer Cell Migration and Invasion by Activating AKT/mTOR/Rac1 Signaling and Actin Reorganization. PLoS ONE 7(12): e52397. doi:10.1371/journal.pone.0052397.

Kasinski, AL. et. al. (2014) A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene. doi:10.1038/onc.2014.282.

Li, N., et al. (2016) miR-182 Modulates Myocardial Hypertrophic Response Induced by Angiogenesis in Heart. Scientific Reports. 6:21228. doi: 10.1038/srep21228.

Liu, C. et al. (January 16, 2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nature Medicine doi:10.1038/nm.2284 Letter.

Liu, X. et al. (2015) The Regulation and Function of miR-21-FOXO3a-miR-34b/c Signaling in Breast Cancer. Int. J. Mol. Sci. 2015, 16, 3148-3162; doi:10.3390/ijms16023148.

Luna C, Li G, Huang J, Qiu J, Wu J, et al. (2012) Regulation of Trabecular Meshwork Cell Contraction and Intraocular Pressure by miR-200c. PLoS ONE 7(12): e51688. doi:10.1371/journal.pone.0051688.

Maa, D.,  Lub, H., Qua, Y., Fuc, W. and Ma, Z. (2014) Developing an effective therapeutic by delivery of synthetic microRNA-520e in lung cancer treatment. Biomedicine & Pharmacotherapy. doi:10.1016/j.biopha.2014.12.009.

Morelli, E., et al. (2015) Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. Leukemia 29, 2173–2183. doi:10.1038/leu.2015.124

Park A-M, Kanai K, Itoh T, Sato T, Tsukui T, Inagaki Y, et al. (2016) Heat Shock Protein 27 Plays a Pivotal Role in Myofibroblast Differentiation and in the Development of Bleomycin-Induced Pulmonary Fibrosis. PLoS ONE 11(2): e0148998. doi:10.1371/ journal.pone.0148998

Saha, M., Abdi, J., Yang, Y., and Chang, H. (2016) miRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc. Oncotarget. 7:6. 

Sun, CY., She XM., et al. (Oct 26, 2012) miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis.

Tian, Y., et al. (2015) A microRNA-Hippo pathway that promotes cardiomyocyte proliferation and cardiac regeneration in mice. Sci Transl Med. 7:279ra38. doi: 10.1126/scitranslmed.3010841.

Trang, P. et al. (March 22, 2011) Systemic Delivery of Tumor Suppressor microRNA Mimics Using a Neutral Lipid Emulsion Inhibits Lung Tumors in Mice. Molecular Therapy doi:10.1038/mt.2011.48.

Wallace, E., et al. (2015) A Sex-specific MicroRNA-96/5HT1B Axis Influences Development of Pulmonary Hypertension. Am J Respir Crit Care Med. Doi: 10.1164/rccm.201412-21480C.

Wang, L. et al. (2012) Loss of miR-29 in Myoblasts Contributes to Dystrophic Muscle Pathogenesis. Molecular Therapy doi:10.1038/mt.2012.35.

Wanga, H., Jianga, Y., Penga, H., Chena, Y., Zhub, P. and Huanga, Y. (2014) Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors. Advanced Drug Delivery Reviews. doi: 10.1016/j.addr.2014.10.031.

Wiggins, J.F. et al. (July 15, 2010) Development of a Lung Cancer Therapeutic Based on the Tumor Suppressor MicroRNA-34. Cancer Res. 70:5923-5930.

Wu, Y et al. (2011) MicroRNA Delivery by Cationic Lipoplexes for Lung Cancer Therapy. Mol. Pharmaceutics. 8, 1381–1389.

Wu Y, Crawford M et al. (2013) Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer. Molecular Therapy Nucleic Acids(2): e84. doi:10.1038/mtna.2013.14.

Zhang, Y., Wang, Z. and Gemeinhart, R. A. (2013) Progress in microRNA delivery. J Control Release. 172:3, 962-74.

Zhao, D., Lu, X. et. al. (2017) Synthetic essentiality of chromatin remodeling factor CHD1 in PTEN deficient cancer. Nature. 2017 February 23; 542(7642): 484–488. doi:10.1038/nature21357.

Kit Specs

TESTS PER KIT: The kit has the capacity for 20 injections.
SHELF LIFE: The shelf life of the kit is 12 months at -20ºC before the RNAi agent is added to the vial and 3 months at -80ºC once the RNAi agent has been added to the vial.